SA518400135B1 - T مولد ضد خيمري ومستقبلات خلية وطرق استخدامها - Google Patents
T مولد ضد خيمري ومستقبلات خلية وطرق استخدامهاInfo
- Publication number
- SA518400135B1 SA518400135B1 SA518400135A SA518400135A SA518400135B1 SA 518400135 B1 SA518400135 B1 SA 518400135B1 SA 518400135 A SA518400135 A SA 518400135A SA 518400135 A SA518400135 A SA 518400135A SA 518400135 B1 SA518400135 B1 SA 518400135B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- chimeric antigen
- methods
- cell receptors
- tcr
- car
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 6
- 108091008874 T cell receptors Proteins 0.000 title abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70589—CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
يتعلق الاختراع الحالي بتقديم مستقبل مولد ضد خيمري chimeric antigen receptor (CAR)، أو مستقبل خلية T (TCR) T cell receptor يشتمل على نطاق خارج الخلايا تم الكشف عنه في الطلب الحالي. تتعلق بعض جوانب الاختراع ببولي نيوكليوتيد polynucleotide يشفر مستقبل مولد ضد خيمري chimeric antigen receptor (CAR) أو مستقبل خلية T (TCR) T cell receptor يشتمل على نطاق خارج الخلايا extracellular domain تم الكشف عنه في الطلب الحالي. تتعلق الجوانب الأخرى من الاختراع بخلايا تشتمل على CAR أو TCR واستخدامها في علاج خلية T. شكل 1ب.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317258P | 2016-04-01 | 2016-04-01 | |
PCT/US2017/025351 WO2017173256A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric antigen and t cell receptors and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SA518400135B1 true SA518400135B1 (ar) | 2022-03-03 |
Family
ID=59960588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA518400135A SA518400135B1 (ar) | 2016-04-01 | 2018-09-30 | T مولد ضد خيمري ومستقبلات خلية وطرق استخدامها |
Country Status (29)
Country | Link |
---|---|
US (2) | US10603380B2 (ar) |
EP (2) | EP3436079B1 (ar) |
JP (2) | JP7034934B2 (ar) |
KR (2) | KR102584280B1 (ar) |
CN (1) | CN109328074A (ar) |
AR (2) | AR108427A1 (ar) |
AU (2) | AU2017240667C1 (ar) |
BR (1) | BR112018070073A2 (ar) |
CA (1) | CA3019149A1 (ar) |
CL (2) | CL2018002762A1 (ar) |
CO (1) | CO2018010453A2 (ar) |
CR (1) | CR20180461A (ar) |
CU (1) | CU20180121A7 (ar) |
DO (1) | DOP2018000213A (ar) |
EA (1) | EA201891965A1 (ar) |
EC (1) | ECSP18073833A (ar) |
ES (1) | ES2891578T3 (ar) |
IL (2) | IL303785A (ar) |
MX (2) | MX2018012017A (ar) |
PE (1) | PE20190173A1 (ar) |
PH (1) | PH12018550163A1 (ar) |
PL (1) | PL3436079T3 (ar) |
PT (1) | PT3436079T (ar) |
SA (1) | SA518400135B1 (ar) |
SG (2) | SG11201808411RA (ar) |
SI (1) | SI3436079T1 (ar) |
SV (1) | SV2018005756A (ar) |
TW (3) | TW202313671A (ar) |
WO (1) | WO2017173256A1 (ar) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP3302507B1 (en) | 2015-05-28 | 2023-02-22 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Diagnostic methods for t cell therapy |
IL305621A (en) | 2015-05-28 | 2023-11-01 | Us Health | Methods for training patients for T-cell therapy |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
SG11201808270PA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
SI3436435T1 (sl) | 2016-03-31 | 2021-08-31 | Janssen Pharmaceuticals, Inc. | Substituirani derivati indolina kot zaviralci replikacije virusa denga |
JP7007290B2 (ja) | 2016-04-01 | 2022-01-24 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | デングウイルス複製阻害剤としての置換インドール化合物誘導体 |
CR20210084A (es) | 2016-04-01 | 2021-03-26 | Amgen Inc | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CN109328074A (zh) | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
CN117903307A (zh) | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
CR20180531A (es) | 2016-04-08 | 2019-06-13 | Immunocore Ltd | Receptores de células t |
JP7109789B2 (ja) * | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 |
WO2018057585A1 (en) | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
JP7217970B2 (ja) | 2016-10-07 | 2023-02-06 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いてt細胞受容体をリプログラミングするための組成物及び方法 |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
FI3618842T3 (fi) | 2017-05-01 | 2023-12-15 | Juno Therapeutics Inc | Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä |
US11622977B2 (en) | 2017-05-12 | 2023-04-11 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
AU2018274100B2 (en) | 2017-05-22 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
IL270727B2 (en) | 2017-05-22 | 2023-03-01 | Janssen Pharmaceuticals Inc | Transduced indulin derivatives as inhibitors of dengue virus replication |
AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
CN109748968B (zh) * | 2017-11-03 | 2020-12-01 | 西安宇繁生物科技有限责任公司 | Bcma特异性嵌合抗原受体t细胞及其应用 |
EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
US11390655B2 (en) * | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
US20210207080A1 (en) | 2017-12-08 | 2021-07-08 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
SG11202005272SA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
CN109957016A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd38的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
CN109957021A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd38的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
WO2019136273A1 (en) * | 2018-01-05 | 2019-07-11 | NantBio Inc. | Reprogrammed t cell-like nk cells |
SG11202008796VA (en) * | 2018-03-14 | 2020-10-29 | The United States Of America As Represented By The Secretary | Anti-cd33 chimeric antigen receptors and their uses |
US20210060072A1 (en) | 2018-05-11 | 2021-03-04 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
WO2019232510A1 (en) | 2018-06-01 | 2019-12-05 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
AU2019284649A1 (en) * | 2018-06-12 | 2021-01-14 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptor tumor infiltrating lymphocytes |
CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
AU2019299555A1 (en) * | 2018-07-04 | 2021-02-25 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1 |
EA202190469A1 (ru) | 2018-08-09 | 2021-06-28 | Джуно Терапьютикс, Инк. | Способы оценки интегрированных нуклеиновых кислот |
KR20210057730A (ko) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
WO2020072352A1 (en) * | 2018-10-01 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car-t cells targeting glioma stem cells for the treatment of glioblastoma multiforme |
SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
AU2019374103A1 (en) | 2018-11-01 | 2021-05-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) |
CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
CN114258430A (zh) * | 2019-04-22 | 2022-03-29 | T细胞受体治疗公司 | 使用融合蛋白进行tcr重编程的组合物和方法 |
CN114007642A (zh) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | 嵌合受体及其使用方法 |
EP3962535A1 (en) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
BR112021026832A2 (pt) | 2019-07-02 | 2022-05-10 | Hutchinson Fred Cancer Res | Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada |
SG10201907378QA (en) * | 2019-08-08 | 2021-03-30 | Nat Univ Singapore | Genetically modified nk cells and uses thereof |
KR20220062500A (ko) * | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
CA3157613A1 (en) * | 2019-11-20 | 2021-05-27 | Gi Cell, Inc. | Medium composition for culturing t cells and method for culturing t cells using same |
KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 형질도입 방법 |
CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
BR112022015968A2 (pt) | 2020-02-12 | 2022-10-11 | Juno Therapeutics Inc | Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas |
CN111269326A (zh) | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
WO2021202592A2 (en) * | 2020-03-30 | 2021-10-07 | Oregon Health & Science University | Monoclonal antibodies for intracellular delivery of payloads |
CN115916223A (zh) | 2020-04-10 | 2023-04-04 | 朱诺治疗学股份有限公司 | 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途 |
KR20230015921A (ko) | 2020-04-28 | 2023-01-31 | 주노 쎄러퓨티크스 인코퍼레이티드 | Bcma-지시된 t 세포 요법 및 면역 조절 화합물의 조합 |
CN111518219B (zh) * | 2020-05-08 | 2021-06-22 | 浙江大学 | 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用 |
WO2021228999A1 (en) * | 2020-05-12 | 2021-11-18 | Institut Curie | Neoantigenic epitopes associated with sf3b1 mutations |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
KR20230117106A (ko) * | 2020-10-12 | 2023-08-07 | 에이치피브이백스, 엘엘씨. | 제1 치료 활성 성분으로서의 백신을 제2 활성 성분과 조합하여 사용하여 암을 치료하기 위한 조성물 및 방법 |
EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
CN117396607A (zh) | 2020-12-30 | 2024-01-12 | 阿劳诺斯治疗公司 | 包含多顺反子表达盒的重组载体及其使用方法 |
US20240108654A1 (en) | 2021-03-03 | 2024-04-04 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
AU2022241654A1 (en) | 2021-03-22 | 2023-09-28 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
CA3214683A1 (en) | 2021-04-16 | 2022-10-20 | Julie Ann RYTLEWSKI | Combination therapies with bcma-directed t cell therapy |
IL307598A (en) | 2021-04-16 | 2023-12-01 | Juno Therapeutics Inc | T-cell therapy in patients who have had a previous stem cell transplant |
CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
CN114121142B (zh) * | 2021-09-02 | 2023-10-31 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024124132A1 (en) | 2022-12-09 | 2024-06-13 | Juno Therapeutics, Inc. | Machine learning methods for predicting cell phenotype using holographic imaging |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
ES2593583T3 (es) | 2009-03-10 | 2016-12-09 | Biogen Ma Inc. | Anticuerpos anti-BCMA |
JP5934099B2 (ja) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用 |
MX2012005719A (es) | 2009-11-17 | 2012-07-30 | Basf Plant Science Co Gmbh | Plantas con rendimiento aumentado. |
US20130079246A1 (en) | 2010-05-05 | 2013-03-28 | Addex Pharma Sa | Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
EP3012268B1 (en) | 2010-09-08 | 2017-11-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
US9845362B2 (en) * | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
DK3415531T3 (da) | 2011-05-27 | 2023-09-18 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17)-bindende proteiner |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
CA3209571A1 (en) * | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
EP2836239A1 (en) | 2012-04-11 | 2015-02-18 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
CN110511278A (zh) * | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
AU2014214850C1 (en) | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
CA2901115A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
KR102095700B1 (ko) | 2013-05-14 | 2020-04-01 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (car) t-세포의 인간 적용 |
DK3027204T3 (da) | 2013-07-29 | 2022-04-19 | 2Seventy Bio Inc | Flerdelte signaleringsproteiner og anvendelser deraf |
CA2930587A1 (en) * | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
CA2937938A1 (en) | 2014-02-04 | 2015-08-13 | Kite Pharma, Inc. | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
AR101829A1 (es) | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
RU2747457C2 (ru) | 2014-07-24 | 2021-05-05 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
BR112017005245A2 (pt) | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
IL308324A (en) | 2014-09-19 | 2024-01-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
BR112017011893A2 (pt) | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
PT3628687T (pt) | 2014-12-12 | 2021-10-20 | Bluebird Bio Inc | Recetores do antigénio quimérico bcma |
BR112017019914A2 (pt) | 2015-04-13 | 2018-06-19 | Pfizer | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b |
DK3283106T3 (da) | 2015-04-13 | 2022-01-10 | Pfizer | Terapeutiske antistoffer og anvendelser deraf |
IL305621A (en) | 2015-05-28 | 2023-11-01 | Us Health | Methods for training patients for T-cell therapy |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
CN109328074A (zh) | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
CR20210084A (es) * | 2016-04-01 | 2021-03-26 | Amgen Inc | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
CN117903307A (zh) * | 2016-04-01 | 2024-04-19 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
MY201207A (en) | 2016-04-01 | 2024-02-09 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
-
2017
- 2017-03-31 CN CN201780030898.9A patent/CN109328074A/zh active Pending
- 2017-03-31 EP EP17776766.2A patent/EP3436079B1/en active Active
- 2017-03-31 TW TW111146001A patent/TW202313671A/zh unknown
- 2017-03-31 PL PL17776766T patent/PL3436079T3/pl unknown
- 2017-03-31 TW TW106111228A patent/TWI691596B/zh active
- 2017-03-31 ES ES17776766T patent/ES2891578T3/es active Active
- 2017-03-31 TW TW109112511A patent/TWI787599B/zh active
- 2017-03-31 WO PCT/US2017/025351 patent/WO2017173256A1/en active Application Filing
- 2017-03-31 CU CU2018000121A patent/CU20180121A7/es unknown
- 2017-03-31 US US15/475,681 patent/US10603380B2/en active Active
- 2017-03-31 KR KR1020227026040A patent/KR102584280B1/ko active IP Right Grant
- 2017-03-31 SG SG11201808411RA patent/SG11201808411RA/en unknown
- 2017-03-31 BR BR112018070073-8A patent/BR112018070073A2/pt not_active Application Discontinuation
- 2017-03-31 AU AU2017240667A patent/AU2017240667C1/en active Active
- 2017-03-31 IL IL303785A patent/IL303785A/en unknown
- 2017-03-31 JP JP2018550787A patent/JP7034934B2/ja active Active
- 2017-03-31 CR CR20180461A patent/CR20180461A/es unknown
- 2017-03-31 PT PT17776766T patent/PT3436079T/pt unknown
- 2017-03-31 PE PE2018001933A patent/PE20190173A1/es not_active Application Discontinuation
- 2017-03-31 AR ARP170100823A patent/AR108427A1/es unknown
- 2017-03-31 CA CA3019149A patent/CA3019149A1/en active Pending
- 2017-03-31 EP EP21192459.2A patent/EP3984559A1/en active Pending
- 2017-03-31 IL IL261941A patent/IL261941B2/en unknown
- 2017-03-31 SI SI201730928T patent/SI3436079T1/sl unknown
- 2017-03-31 EA EA201891965A patent/EA201891965A1/ru unknown
- 2017-03-31 SG SG10201912489QA patent/SG10201912489QA/en unknown
- 2017-03-31 KR KR1020187031270A patent/KR102427334B1/ko active IP Right Grant
- 2017-03-31 MX MX2018012017A patent/MX2018012017A/es unknown
-
2018
- 2018-09-27 CL CL2018002762A patent/CL2018002762A1/es unknown
- 2018-09-27 PH PH12018550163A patent/PH12018550163A1/en unknown
- 2018-09-28 CO CONC2018/0010453A patent/CO2018010453A2/es unknown
- 2018-09-30 SA SA518400135A patent/SA518400135B1/ar unknown
- 2018-10-01 SV SV2018005756A patent/SV2018005756A/es unknown
- 2018-10-01 EC ECSENADI201873833A patent/ECSP18073833A/es unknown
- 2018-10-01 DO DO2018000213A patent/DOP2018000213A/es unknown
- 2018-10-01 MX MX2022003995A patent/MX2022003995A/es unknown
-
2019
- 2019-09-13 US US16/570,645 patent/US20200108142A1/en not_active Abandoned
- 2019-09-26 CL CL2019002739A patent/CL2019002739A1/es unknown
-
2021
- 2021-02-11 AR ARP210100357A patent/AR121318A2/es unknown
-
2022
- 2022-03-02 JP JP2022031538A patent/JP7379561B2/ja active Active
- 2022-06-23 AU AU2022204423A patent/AU2022204423A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518400135B1 (ar) | T مولد ضد خيمري ومستقبلات خلية وطرق استخدامها | |
MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
MX2022009463A (es) | Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso. | |
MX2021006400A (es) | Celulas t de memoria central para terapia adoptiva de celulas t. | |
PH12019501227A1 (en) | Synthetic immune receptors and methods of use thereof | |
MX2021008498A (es) | Celulas t modificadas en receptor de antigeno quimerico dirigo a cs1. | |
MX2018000278A (es) | Terapia de receptores quimericos de puntos de control inmunitarios. | |
MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
CL2016002195A1 (es) | Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta | |
MX2018012019A (es) | Receptores quimericos y metodos de uso de los mismos. | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
MX2020007266A (es) | Moleculas del receptor quimerico de engullido y metodos de uso. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
MX2017003640A (es) | Receptores antigenicos quimericos. | |
MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
IL257295B (en) | Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured | |
MX2016002027A (es) | Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos. | |
GB201721831D0 (en) | T cell antigen receptor chimera |